Deferoxamine Therapy for Hemorrhagic Transformation Following Brain Ischemia

The risk of HT increases after reperfusion therapies, such as tissue plasminogen activator (tPA) and mechanical thrombectomy [3], and it limits the use of such therapies. When large enough to form a parenchymal hematoma, HT is associated with increased risk of death and disability [5]. [...]there are extensive efforts to develop adjunct therapies to be given with tPA or thrombectomy to limit HT (e.g., NCT0222274, NCT05484154, NCT05035953). Hao, Z; Yang, C; Xiang, L; Wu, B; Liu, M. Risk factors for intracranial hemorrhage after mechanical thrombectomy: a systematic review and meta-analysis. Targeting pro-oxidant iron with deferoxamine as a treatment for ischemic stroke: safety and optimal dose selection in a randomized clinical trial.